{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:32:39Z","timestamp":1794702759253,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41591-026-04502-7","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:29:56Z","timestamp":1783070996000},"page":"3010-3022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Generalizable AI predicts immunotherapy outcomes across cancers and treatments"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7114-3664","authenticated-orcid":false,"given":"Wanxiang","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intae","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6660-6556","authenticated-orcid":false,"given":"Thinh H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0223-7485","authenticated-orcid":false,"given":"Michelle M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yepeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-9313","authenticated-orcid":false,"given":"Nitya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6686-9249","authenticated-orcid":false,"given":"Daniel","family":"Marbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-7228","authenticated-orcid":false,"given":"Marinka","family":"Zitnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"4502_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong, J., Chehrazi-Raffle, A., Reddi, S. & Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer 6, 8 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"4502_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19, 133\u2013150 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"4502_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang, M. M., Coupland, S. E., Aittokallio, T. & Figueiredo, C. R. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br. J. Cancer 129, 1212\u20131224 (2023).","journal-title":"Br. J. Cancer"},{"key":"4502_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"4502_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"4502_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949 (2017).","journal-title":"Cell"},{"key":"4502_CR7","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"4502_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545\u20131549 (2018).","journal-title":"Nat. Med."},{"key":"4502_CR9","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"4502_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27651-4","volume":"13","author":"C-C Wu","year":"2022","unstructured":"Wu, C.-C., Wang, Y. A., Livingston, J. A., Zhang, J. & Futreal, P. A. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. Nat. Commun. 13, 42 (2022).","journal-title":"Nat. Commun."},{"key":"4502_CR11","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"4502_CR12","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.ccell.2024.10.017","volume":"42","author":"D Hsiehchen","year":"2024","unstructured":"Hsiehchen, D. et al. Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation. Cancer Cell 42, 1985\u20131987 (2024).","journal-title":"Cancer Cell"},{"key":"4502_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.medj.2022.11.001","volume":"4","author":"G Dinstag","year":"2023","unstructured":"Dinstag, G. et al. Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med 4, 15\u201330 (2023).","journal-title":"Med"},{"key":"4502_CR14","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s43018-024-00793-2","volume":"5","author":"D-T Hoang","year":"2024","unstructured":"Hoang, D.-T. et al. A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics. Nat. Cancer 5, 1305\u20131317 (2024).","journal-title":"Nat. Cancer"},{"key":"4502_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010132","volume":"13","author":"J Arnon","year":"2025","unstructured":"Arnon, J. et al. Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics. J. Immunother. Cancer 13, e010132 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"4502_CR16","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.patter.2021.100293","volume":"2","author":"\u00d3 Lapuente-Santana","year":"2021","unstructured":"Lapuente-Santana, \u00d3, van Genderen, M., Hilbers, P. A., Finotello, F. & Eduati, F. Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. Patterns 2, 100293 (2021).","journal-title":"Patterns"},{"key":"4502_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jare.2024.07.036","volume":"72","author":"Y Jiang","year":"2025","unstructured":"Jiang, Y. et al. IRnet: immunotherapy response prediction using pathway knowledge-informed graph neural network. J. Adv. Res. 72, 319\u2013331 (2025).","journal-title":"J. Adv. Res."},{"key":"4502_CR18","unstructured":"Koh, P. W. et al. Concept bottleneck models. In Proc. of the 37th International Conference on Machine Learning 5338\u20135348 (PMLR, 2020); https:\/\/proceedings.mlr.press\/v119\/koh20a.html"},{"key":"4502_CR19","doi-asserted-by":"crossref","unstructured":"Bergstrom, E. N. & Alexandrov, L. B. Enhanced precision in immunotherapy. Nat. Cancer 5, 1136\u20131138 (2024).","DOI":"10.1038\/s43018-024-00802-4"},{"key":"4502_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","volume":"40","author":"D Chowell","year":"2022","unstructured":"Chowell, D. et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat. Biotechnol. 40, 499\u2013506 (2022).","journal-title":"Nat. Biotechnol."},{"key":"4502_CR21","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"4502_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).","journal-title":"Lancet"},{"key":"4502_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"4502_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008185","volume":"12","author":"A Roller","year":"2024","unstructured":"Roller, A. et al. Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials. J. Immunother. Cancer 12, e008185 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"4502_CR25","doi-asserted-by":"crossref","unstructured":"Montauti, E., Oh, D. Y. & Fong, L. CD4+ T cells in antitumor immunity. Trends Cancer 10, 969\u2212985 (2024).","DOI":"10.1016\/j.trecan.2024.07.009"},{"key":"4502_CR26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"4502_CR27","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.annonc.2020.07.013","volume":"31","author":"T Becker","year":"2020","unstructured":"Becker, T. et al. An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort. Ann. Oncol. 31, 1561\u20131568 (2020).","journal-title":"Ann. Oncol."},{"key":"4502_CR28","doi-asserted-by":"crossref","unstructured":"Chang, T.-G. et al. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features. Nat. Cancer 5, 1158\u20131175 (2024).","DOI":"10.1038\/s43018-024-00772-7"},{"key":"4502_CR29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s43018-022-00416-8","volume":"3","author":"RS Vanguri","year":"2022","unstructured":"Vanguri, R. S. et al. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer. Nat. Cancer 3, 1151\u20131164 (2022).","journal-title":"Nat. Cancer"},{"key":"4502_CR30","doi-asserted-by":"crossref","unstructured":"Yoo, S.-K. et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat. Med. 31, 869\u2013880 (2025).","DOI":"10.1038\/s41591-024-03398-5"},{"key":"4502_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57181-2","volume":"16","author":"G Arango-Argoty","year":"2025","unstructured":"Arango-Argoty, G. et al. Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers. Nat. Commun. 16, 2101 (2025).","journal-title":"Nat. Commun."},{"key":"4502_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06139-9","volume":"618","author":"CV Theodoris","year":"2023","unstructured":"Theodoris, C. V. et al. Transfer learning enables predictions in network biology. Nature 618, 616\u2013624 (2023).","journal-title":"Nature"},{"key":"4502_CR33","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/s41592-024-02341-3","volume":"21","author":"MM Li","year":"2024","unstructured":"Li, M. M. et al. Contextual AI models for single-cell protein biology. Nat. Methods 21, 1546\u20131557 (2024).","journal-title":"Nat. Methods"},{"key":"4502_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749\u2013757 (2018).","journal-title":"Nat. Med."},{"key":"4502_CR35","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","volume":"55","author":"A Ravi","year":"2023","unstructured":"Ravi, A. et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat. Genet. 55, 807\u2013819 (2023).","journal-title":"Nat. Genet."},{"key":"4502_CR36","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916\u20131927 (2019).","journal-title":"Nat. Med."},{"key":"4502_CR37","doi-asserted-by":"crossref","unstructured":"Freeman, S. S. et al. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep. Med. 3, 100500 (2022).","DOI":"10.1016\/j.xcrm.2021.100500"},{"key":"4502_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"4502_CR39","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24, 1449\u20131458 (2018).","journal-title":"Nat. Med."},{"key":"4502_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255 (2019).","journal-title":"Cancer Cell"},{"key":"4502_CR41","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose, T. L. et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br. J. Cancer 125, 1251\u20131260 (2021).","journal-title":"Br. J. Cancer"},{"key":"4502_CR42","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","volume":"22","author":"TK Choueiri","year":"2016","unstructured":"Choueiri, T. K. et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. Cancer Res. 22, 5461\u20135471 (2016).","journal-title":"Clin. Cancer Res."},{"key":"4502_CR43","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801\u2013806 (2018).","journal-title":"Science"},{"key":"4502_CR44","doi-asserted-by":"publisher","first-page":"e1002309","DOI":"10.1371\/journal.pmed.1002309","volume":"14","author":"A Snyder","year":"2017","unstructured":"Snyder, A. et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis. PLoS Med. 14, e1002309 (2017).","journal-title":"PLoS Med."},{"key":"4502_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"4502_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"4502_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31535-6","volume":"13","author":"J Kong","year":"2022","unstructured":"Kong, J. et al. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat. Commun. 13, 3703 (2022).","journal-title":"Nat. Commun."},{"key":"4502_CR48","doi-asserted-by":"publisher","first-page":"eaaf8399","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).","journal-title":"Science"},{"key":"4502_CR49","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016).","journal-title":"Lancet"},{"key":"4502_CR50","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454\u2013461 (2019).","journal-title":"Nat. Med."},{"key":"4502_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"4502_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/srep00765","volume":"2","author":"JL Messina","year":"2012","unstructured":"Messina, J. L. et al. 12-chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).","journal-title":"Sci. Rep."},{"key":"4502_CR53","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.32193","volume":"146","author":"M Nurmik","year":"2020","unstructured":"Nurmik, M., Ullmann, P., Rodriguez, F., Haan, S. & Letellier, E. In search of definitions: cancer-associated fibroblasts and their markers. Int. J. Cancer 146, 895\u2013905 (2020).","journal-title":"Int. J. Cancer"},{"key":"4502_CR54","doi-asserted-by":"publisher","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"W Roh","year":"2017","unstructured":"Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017).","journal-title":"Sci. Transl. Med."},{"key":"4502_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"4502_CR56","unstructured":"Gorishniy, Y., Rubachev, I., Khrulkov, V. & Babenko, A. Revisiting deep learning models for tabular data. In NIPS\u02bc21: Proceedings of the 35th International Conference on Neural Information Processing Systems (eds Ranzato, M. et al.) 18932\u201318943 (Curran Associates, 2021)."},{"key":"4502_CR57","unstructured":"Choromanski, K. et al. Rethinking attention with performers. In International Conference on Learning Representations https:\/\/openreview.net\/pdf?id=Ua6zuk0WRH (2021)."},{"key":"4502_CR58","unstructured":"Snell, J., Swersky, K. & Zemel, R. Prototypical networks for few-shot learning. In NIPS\u02bc17: Proceedings of the 31st International Conference on Neural Information Processing Systems (eds von Luxburg, U. et al.) 4080\u22124090 (Curran Associates, 2017)."},{"key":"4502_CR59","unstructured":"Lundberg, S. M. & Lee, S.-I. A unified approach to interpreting model predictions. In 31st Conference on Neural Information Processing Systems (eds Guyon, I. et al.) 4765\u20134774 (Curran Associates, 2017)."},{"key":"4502_CR60","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416 (2018).","journal-title":"Cell"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04502-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:01:52Z","timestamp":1786629712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4502"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04502-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.M. and N.N. are currently employed by F. Hoffmann-La Roche Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}